ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient ...

A psychosocial intervention designed to improve depressive symptoms and promote good parenting skills can be an effective way of treating male postpartum depression, according to new research. In a ...

(RTTNews) - Lipocine Inc. (LPCN), a biopharmaceutical company specializing in oral drug delivery, has commenced a Phase 3 trial for LPCN 1154 (oral brexanolone), an investigational treatment for ...

You can often use therapy and medication together to treat postpartum depression (PPD). Cognitive behavioral therapy (CBT) helps manage negative thoughts and is effective for PPD. Zuranolone is an FDA ...

The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for ...

New parents are told to expect tears, mood swings, and sleep deprivation, then sent home with a newborn and a "you've got this." For many, those early emotional whiplash days really are a short‑lived ...

SCIENTISTS ARE LOOKING AT THE PSYCHEDELIC DRUG AS A TREATMENT FOR POSTPARTUM DEPRESSION. WESH 2 NEWS JILLIAN CAMPBELL TALKED WITH A MOM AND DOCTORS WHO SAY THIS COULD BE THE MEDICINE OF THE FUTURE.

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat ...

Increasing attention to maternal mental health, early diagnosis, and the development of new, rapidly-acting drug treatments is propelling the market forward at a rapid pace.Austin, Texas, Jan. 22, ...

LOS ANGELES -- Hayden Panettiere is entering treatment for postpartum depression. A spokeswoman for the actress says in a statement that the "Nashville" star is voluntarily seeking professional help ...

SALT LAKE CITY, June 23, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics ...